Suzhou Fushilai Pharmaceutical Co. Ltd. (301258.SZ) stock: key figures, P/E, revenue and dividend

Health Care · Biotechnology · China · ISIN CNE1000058W2

Price
23.35 CNY
Market cap
2.14 bn CNY
P/E (2025)
33.29
P/S (2025)
4.95
Dividend yield
0.94 %
Net margin
14.86 %
Return on equity (ROE)
3.45 %
Return on assets (ROA)
3.03 %

Suzhou Fushilai Pharmaceutical Co. Ltd. financials

Fiscal year20242025
Revenue429.47 m CNY432.73 m CNY
Gross profit84.30 m CNY72.21 m CNY
Operating income-1.23 m CNY-8.10 m CNY
EBIT18.30 m CNY74.91 m CNY
Net income16.41 m CNY64.29 m CNY
Diluted EPS – continuing operations0.18 CNY0.70 CNY

Full history since 2019, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

Sign up for freeOpen interactive view

About Suzhou Fushilai Pharmaceutical Co. Ltd.

Suzhou Fushilai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and health care raw materials in China and internationally. The company offers lipoic acid products comprising granular alpha lipoic acid, R-lipoic acid, r-lipoic acid tromethamine salt, and 6,8-dichlorooctanoic acid ethyl ester; L-carnosine; phosphatidylcholine products, which include glycerylphosphatidylcholine; and erelcoxib API, a nonsteroidal anti-inflammatory analgesic used to relieve the pain symptoms of osteoarthritis. Its products are used in medicines, dietary supplements, and cosmetics applications. The company also engages in research and experimental development and capital market activities. Suzhou Fushilai Pharmaceutical Co., Ltd. was founded in 2000 and is based in Changshu, China.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.